Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia

IntroductionImpaired awareness of hypoglycemia (IAH) is a common complication in patients with type-1 diabetes (T1D). IAH is a major risk factor for severe hypoglycemic events, leading to adverse clinical consequences and cerebral damage. Non-invasive, cost-effective, and logistically efficient biom...

Full description

Saved in:
Bibliographic Details
Published in:BMJ open diabetes research & care 2020-07, Vol.8 (1), p.e001516
Main Authors: Sampedro, Frederic, Stantonyonge, Nicole, Martínez-Horta, Saül, Alcolea, Daniel, Lleó, Alberto, Muñoz, Laia, Pérez-González, Rocío, Marín-Lahoz, Juan, Gómez-Ansón, Beatriz, Chico, Ana
Format: Article
Language:English
Subjects:
Biomarkers
Brain damage
Brain research
Diabetes
Glucose
Hypoglycemia
Insulin
Logistics
Medical imaging
Pathophysiology/Complications
Plasma
Sociodemographics
Variance analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-b511t-e8114a32574e216bb176a7817912fa82ebd7819761a13b42ded2e96158edbeec3
cites cdi_FETCH-LOGICAL-b511t-e8114a32574e216bb176a7817912fa82ebd7819761a13b42ded2e96158edbeec3
container_end_page
container_issue 1
container_start_page e001516
container_title BMJ open diabetes research & care
container_volume 8
creator Sampedro, Frederic
Stantonyonge, Nicole
Martínez-Horta, Saül
Alcolea, Daniel
Lleó, Alberto
Muñoz, Laia
Pérez-González, Rocío
Marín-Lahoz, Juan
Gómez-Ansón, Beatriz
Chico, Ana
description IntroductionImpaired awareness of hypoglycemia (IAH) is a common complication in patients with type-1 diabetes (T1D). IAH is a major risk factor for severe hypoglycemic events, leading to adverse clinical consequences and cerebral damage. Non-invasive, cost-effective, and logistically efficient biomarkers for this condition have not been validated. Here, we propose plasma neurofilament light chain (NfL) levels as a biomarker of neuroaxonal damage in patients with T1D-IAH.Research design and methods54 patients were included into the study (18 T1D-IAH, 18 T1D with normal awareness of hypoglycemia (NAH) and 18 healthy controls). We measured plasma NfL levels and studied cerebral gray matter alterations on MRI.ResultsWe found that NfL levels were increased in patients with T1D-IAH compared with patients with T1D-NAH and healthy controls. Importantly, increased NfL levels correlated with reduced cerebral gray matter volume and increased IAH severity in patients with T1D-IAH.ConclusionOverall, our findings identify plasma NfL levels as a potential biomarker of cerebral damage in this population, motivating further confirmatory studies with potential implications in clinical trials.
doi_str_mv 10.1136/bmjdrc-2020-001516
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_7ca181b481dd487b915ad24cd235ed21</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_7ca181b481dd487b915ad24cd235ed21</doaj_id><sourcerecordid>2421466652</sourcerecordid><originalsourceid>FETCH-LOGICAL-b511t-e8114a32574e216bb176a7817912fa82ebd7819761a13b42ded2e96158edbeec3</originalsourceid><addsrcrecordid>eNqNkk9v1DAQxSMEolXpF-BkiQuXQMZ2nOSChCr-VKrEBc7W2J7d9cqJg51ttf30eMkKUU6cPJ735qfR6FXVa2jeAQj13ox7l2zNG97UTQMtqGfVJW9aXst-6J7_VV9U1znvm2ISCkTfvqwuBFdCcQ6X1ePtZBNhJsfmgHlENtEhxY0PONK0sOC3u4XZHfqJBbqnkFmpZlx8UTN78MuOLceZamDOo6GFzk0_zuhTweIDJpooZxY3bHec4zYcLY0eX1UvNhgyXZ_fq-rH50_fb77Wd9--3N58vKtNC7DU1ANIFLztJHFQxkCnsOuhG4BvsOdkXPkNnQIEYSR35DgNCtqenCGy4qq6Xbku4l7PyY-Yjjqi178bMW01psXbQLqzCD0Y2YNzsu_MAC06Lq3joi1YKKwPK2s-mJGcLUdIGJ5AnyqT3-ltvNedkFx2sgDengEp_jxQXvTos6UQcKJ4yJpLDlIp1fJiffOPdR8PaSqnKi4hOO8HcQLy1WVTzDnR5s8y0OhTUvSaFH1Kil6TUobqdaho_-P_Beb3wOk</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2433228934</pqid></control><display><type>article</type><title>Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>British Medical Journal Open Access Journals</source><creator>Sampedro, Frederic ; Stantonyonge, Nicole ; Martínez-Horta, Saül ; Alcolea, Daniel ; Lleó, Alberto ; Muñoz, Laia ; Pérez-González, Rocío ; Marín-Lahoz, Juan ; Gómez-Ansón, Beatriz ; Chico, Ana</creator><creatorcontrib>Sampedro, Frederic ; Stantonyonge, Nicole ; Martínez-Horta, Saül ; Alcolea, Daniel ; Lleó, Alberto ; Muñoz, Laia ; Pérez-González, Rocío ; Marín-Lahoz, Juan ; Gómez-Ansón, Beatriz ; Chico, Ana</creatorcontrib><description>IntroductionImpaired awareness of hypoglycemia (IAH) is a common complication in patients with type-1 diabetes (T1D). IAH is a major risk factor for severe hypoglycemic events, leading to adverse clinical consequences and cerebral damage. Non-invasive, cost-effective, and logistically efficient biomarkers for this condition have not been validated. Here, we propose plasma neurofilament light chain (NfL) levels as a biomarker of neuroaxonal damage in patients with T1D-IAH.Research design and methods54 patients were included into the study (18 T1D-IAH, 18 T1D with normal awareness of hypoglycemia (NAH) and 18 healthy controls). We measured plasma NfL levels and studied cerebral gray matter alterations on MRI.ResultsWe found that NfL levels were increased in patients with T1D-IAH compared with patients with T1D-NAH and healthy controls. Importantly, increased NfL levels correlated with reduced cerebral gray matter volume and increased IAH severity in patients with T1D-IAH.ConclusionOverall, our findings identify plasma NfL levels as a potential biomarker of cerebral damage in this population, motivating further confirmatory studies with potential implications in clinical trials.</description><identifier>ISSN: 2052-4897</identifier><identifier>EISSN: 2052-4897</identifier><identifier>DOI: 10.1136/bmjdrc-2020-001516</identifier><identifier>PMID: 32636221</identifier><language>eng</language><publisher>London: BMJ Publishing Group LTD</publisher><subject>Biomarkers ; Brain damage ; Brain research ; Diabetes ; Glucose ; Hypoglycemia ; Insulin ; Logistics ; Medical imaging ; Pathophysiology/Complications ; Plasma ; Sociodemographics ; Variance analysis</subject><ispartof>BMJ open diabetes research &amp; care, 2020-07, Vol.8 (1), p.e001516</ispartof><rights>Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2020 Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b511t-e8114a32574e216bb176a7817912fa82ebd7819761a13b42ded2e96158edbeec3</citedby><cites>FETCH-LOGICAL-b511t-e8114a32574e216bb176a7817912fa82ebd7819761a13b42ded2e96158edbeec3</cites><orcidid>0000-0001-6498-3411</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2433228934/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2433228934?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25752,27548,27549,27923,27924,37011,37012,44589,53790,53792,74897,77372,77403</link.rule.ids></links><search><creatorcontrib>Sampedro, Frederic</creatorcontrib><creatorcontrib>Stantonyonge, Nicole</creatorcontrib><creatorcontrib>Martínez-Horta, Saül</creatorcontrib><creatorcontrib>Alcolea, Daniel</creatorcontrib><creatorcontrib>Lleó, Alberto</creatorcontrib><creatorcontrib>Muñoz, Laia</creatorcontrib><creatorcontrib>Pérez-González, Rocío</creatorcontrib><creatorcontrib>Marín-Lahoz, Juan</creatorcontrib><creatorcontrib>Gómez-Ansón, Beatriz</creatorcontrib><creatorcontrib>Chico, Ana</creatorcontrib><title>Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia</title><title>BMJ open diabetes research &amp; care</title><description>IntroductionImpaired awareness of hypoglycemia (IAH) is a common complication in patients with type-1 diabetes (T1D). IAH is a major risk factor for severe hypoglycemic events, leading to adverse clinical consequences and cerebral damage. Non-invasive, cost-effective, and logistically efficient biomarkers for this condition have not been validated. Here, we propose plasma neurofilament light chain (NfL) levels as a biomarker of neuroaxonal damage in patients with T1D-IAH.Research design and methods54 patients were included into the study (18 T1D-IAH, 18 T1D with normal awareness of hypoglycemia (NAH) and 18 healthy controls). We measured plasma NfL levels and studied cerebral gray matter alterations on MRI.ResultsWe found that NfL levels were increased in patients with T1D-IAH compared with patients with T1D-NAH and healthy controls. Importantly, increased NfL levels correlated with reduced cerebral gray matter volume and increased IAH severity in patients with T1D-IAH.ConclusionOverall, our findings identify plasma NfL levels as a potential biomarker of cerebral damage in this population, motivating further confirmatory studies with potential implications in clinical trials.</description><subject>Biomarkers</subject><subject>Brain damage</subject><subject>Brain research</subject><subject>Diabetes</subject><subject>Glucose</subject><subject>Hypoglycemia</subject><subject>Insulin</subject><subject>Logistics</subject><subject>Medical imaging</subject><subject>Pathophysiology/Complications</subject><subject>Plasma</subject><subject>Sociodemographics</subject><subject>Variance analysis</subject><issn>2052-4897</issn><issn>2052-4897</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNkk9v1DAQxSMEolXpF-BkiQuXQMZ2nOSChCr-VKrEBc7W2J7d9cqJg51ttf30eMkKUU6cPJ735qfR6FXVa2jeAQj13ox7l2zNG97UTQMtqGfVJW9aXst-6J7_VV9U1znvm2ISCkTfvqwuBFdCcQ6X1ePtZBNhJsfmgHlENtEhxY0PONK0sOC3u4XZHfqJBbqnkFmpZlx8UTN78MuOLceZamDOo6GFzk0_zuhTweIDJpooZxY3bHec4zYcLY0eX1UvNhgyXZ_fq-rH50_fb77Wd9--3N58vKtNC7DU1ANIFLztJHFQxkCnsOuhG4BvsOdkXPkNnQIEYSR35DgNCtqenCGy4qq6Xbku4l7PyY-Yjjqi178bMW01psXbQLqzCD0Y2YNzsu_MAC06Lq3joi1YKKwPK2s-mJGcLUdIGJ5AnyqT3-ltvNedkFx2sgDengEp_jxQXvTos6UQcKJ4yJpLDlIp1fJiffOPdR8PaSqnKi4hOO8HcQLy1WVTzDnR5s8y0OhTUvSaFH1Kil6TUobqdaho_-P_Beb3wOk</recordid><startdate>20200706</startdate><enddate>20200706</enddate><creator>Sampedro, Frederic</creator><creator>Stantonyonge, Nicole</creator><creator>Martínez-Horta, Saül</creator><creator>Alcolea, Daniel</creator><creator>Lleó, Alberto</creator><creator>Muñoz, Laia</creator><creator>Pérez-González, Rocío</creator><creator>Marín-Lahoz, Juan</creator><creator>Gómez-Ansón, Beatriz</creator><creator>Chico, Ana</creator><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-6498-3411</orcidid></search><sort><creationdate>20200706</creationdate><title>Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia</title><author>Sampedro, Frederic ; Stantonyonge, Nicole ; Martínez-Horta, Saül ; Alcolea, Daniel ; Lleó, Alberto ; Muñoz, Laia ; Pérez-González, Rocío ; Marín-Lahoz, Juan ; Gómez-Ansón, Beatriz ; Chico, Ana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b511t-e8114a32574e216bb176a7817912fa82ebd7819761a13b42ded2e96158edbeec3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Biomarkers</topic><topic>Brain damage</topic><topic>Brain research</topic><topic>Diabetes</topic><topic>Glucose</topic><topic>Hypoglycemia</topic><topic>Insulin</topic><topic>Logistics</topic><topic>Medical imaging</topic><topic>Pathophysiology/Complications</topic><topic>Plasma</topic><topic>Sociodemographics</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sampedro, Frederic</creatorcontrib><creatorcontrib>Stantonyonge, Nicole</creatorcontrib><creatorcontrib>Martínez-Horta, Saül</creatorcontrib><creatorcontrib>Alcolea, Daniel</creatorcontrib><creatorcontrib>Lleó, Alberto</creatorcontrib><creatorcontrib>Muñoz, Laia</creatorcontrib><creatorcontrib>Pérez-González, Rocío</creatorcontrib><creatorcontrib>Marín-Lahoz, Juan</creatorcontrib><creatorcontrib>Gómez-Ansón, Beatriz</creatorcontrib><creatorcontrib>Chico, Ana</creatorcontrib><collection>British Medical Journal Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMJ open diabetes research &amp; care</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sampedro, Frederic</au><au>Stantonyonge, Nicole</au><au>Martínez-Horta, Saül</au><au>Alcolea, Daniel</au><au>Lleó, Alberto</au><au>Muñoz, Laia</au><au>Pérez-González, Rocío</au><au>Marín-Lahoz, Juan</au><au>Gómez-Ansón, Beatriz</au><au>Chico, Ana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia</atitle><jtitle>BMJ open diabetes research &amp; care</jtitle><date>2020-07-06</date><risdate>2020</risdate><volume>8</volume><issue>1</issue><spage>e001516</spage><pages>e001516-</pages><issn>2052-4897</issn><eissn>2052-4897</eissn><abstract>IntroductionImpaired awareness of hypoglycemia (IAH) is a common complication in patients with type-1 diabetes (T1D). IAH is a major risk factor for severe hypoglycemic events, leading to adverse clinical consequences and cerebral damage. Non-invasive, cost-effective, and logistically efficient biomarkers for this condition have not been validated. Here, we propose plasma neurofilament light chain (NfL) levels as a biomarker of neuroaxonal damage in patients with T1D-IAH.Research design and methods54 patients were included into the study (18 T1D-IAH, 18 T1D with normal awareness of hypoglycemia (NAH) and 18 healthy controls). We measured plasma NfL levels and studied cerebral gray matter alterations on MRI.ResultsWe found that NfL levels were increased in patients with T1D-IAH compared with patients with T1D-NAH and healthy controls. Importantly, increased NfL levels correlated with reduced cerebral gray matter volume and increased IAH severity in patients with T1D-IAH.ConclusionOverall, our findings identify plasma NfL levels as a potential biomarker of cerebral damage in this population, motivating further confirmatory studies with potential implications in clinical trials.</abstract><cop>London</cop><pub>BMJ Publishing Group LTD</pub><pmid>32636221</pmid><doi>10.1136/bmjdrc-2020-001516</doi><orcidid>https://orcid.org/0000-0001-6498-3411</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2052-4897
ispartof BMJ open diabetes research & care, 2020-07, Vol.8 (1), p.e001516
issn 2052-4897
2052-4897
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_7ca181b481dd487b915ad24cd235ed21
source Publicly Available Content Database; PubMed Central; British Medical Journal Open Access Journals
subjects Biomarkers
Brain damage
Brain research
Diabetes
Glucose
Hypoglycemia
Insulin
Logistics
Medical imaging
Pathophysiology/Complications
Plasma
Sociodemographics
Variance analysis
title Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T19%3A39%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20plasma%20neurofilament%20light%20chain%20levels%20in%20patients%20with%20type-1%20diabetes%20with%20impaired%20awareness%20of%20hypoglycemia&rft.jtitle=BMJ%20open%20diabetes%20research%20&%20care&rft.au=Sampedro,%20Frederic&rft.date=2020-07-06&rft.volume=8&rft.issue=1&rft.spage=e001516&rft.pages=e001516-&rft.issn=2052-4897&rft.eissn=2052-4897&rft_id=info:doi/10.1136/bmjdrc-2020-001516&rft_dat=%3Cproquest_doaj_%3E2421466652%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-b511t-e8114a32574e216bb176a7817912fa82ebd7819761a13b42ded2e96158edbeec3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2433228934&rft_id=info:pmid/32636221&rfr_iscdi=true